PDS BIOTECHNOLOGY CORPORATION - COMMON STOCK

PDS Biotech Announces Participation in the Channelchek Takeaway Series

26 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech to Participate at the B. Riley Securities 3rd Annual Oncology Conference

13 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany

03 Jan 2023 06:00:01 By Nasdaq GlobeNewswire

PDS Biotech Reports Median Overall Survival (OS) of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 months

28 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer

15 Dec 2022 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Executives to Present an Overview of Oncology and Infectious Disease Programs at the World Vaccine & Immunotherapy Congress

21 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business Update

14 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial

14 Nov 2022 06:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Presentation of Preliminary PDS0101 Efficacy, Safety, and Immunology Data at Society for Immunotherapy of Cancer (SITC 2022)

07 Nov 2022 07:00:03 By Nasdaq GlobeNewswire

PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2022 Financial Results

31 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Provides Highlights from Head and Neck Cancer KOL Roundtable

27 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Chief Medical Officer Dr. Lauren V. Wood to Address 2022 International Head and Neck Conference

25 Oct 2022 07:00:02 By Nasdaq GlobeNewswire

PDS Biotech to Present at the LD Micro Main Event XV

19 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Abstract Demonstrating Versatility of the Versamune® Platform in Oncology Accepted for Presentation at AACR Special Conference on Tumor Immunology and Immunotherapy

17 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech to Host Head and Neck Cancer KOL Roundtable on October 26, 2022

12 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers

11 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Reports An Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

07 Oct 2022 15:01:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Abstracts Involving Research of PDS0101 Accepted for Presentation at SITC 2022

05 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Successful End-of-Phase 2 Meeting With the FDA and Preparation for the Registrational Trial of PDS0101 in Combination With KEYTRUDA®

03 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

23 Sep 2022 15:05:00 By Nasdaq GlobeNewswire